Showing results (1-10 of 92) with videos related to
Sort By:
Pageof 10
The American Review of Respiratory Disease|April 1, 1991
Critical analysis of neoadjuvant therapy for Stage IIIa non-small cell lung cancer [corrected]J R Murren, A C Buzaid, W N HaitThe Journal of Clinical Investigation|May 1, 1993
Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agentsW N Hait, S Choudhury, S Srimatkandada, et al.Biochemical Pharmacology|January 26, 1993
Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cellsW N Hait, J F Gesmonde, J R Murren, et al.Cancer Chemotherapy and Pharmacology|January 1, 1996
Trifluoperazine as a modulator of multidrug resistance in refractory breast cancerJ R Murren, H J Durivage, A C Buzaid, et al.Oncology (Williston Park, N.Y.)|August 11, 2001
Rationale for non-platinum chemotherapy in advanced NSCLCJ R MurrenAnti-Cancer Drug Design|October 1, 1987
Targeting calmodulin for the development of novel cancer chemotherapeutic agentsW N HaitClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2001
The prognostic and predictive values of ECD-HER-2W N HaitAmerican Journal of Clinical Oncology|June 1, 1994
Cisplatin, doxorubicin, mitomycin C, and 5-fluorouracil for the treatment of metastatic non-small cell lung cancer. Limited activity of an aggressive chemotherapy regimenJ R Murren, H J Durivage, A H Rosenberg, et al.Cancer Chemotherapy and Pharmacology|January 1, 1995
Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I studyA C Buzaid, G Pizzorno, J C Marsh, et al.Oncology Research|January 1, 1993
A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancerJ R Murren, S Ganpule, R Papac, et al.Pageof 10